Categories Earnings, Health Care

Sanofi (NASDAQ: SNY): Q3 2019 Earnings Snapshot

— Generic drugmaker Sanofi (NASDAQ: SNY) reported net income of EUR 1.77 billion or EUR 1.49 per share for the third quarter, on IFRS basis, down 23.% and 18.6% respectively from last year

— IFRS net sales increased 1.1% year-over-year to EUR 9.5 billion, on a reported basis

— Sanofi Genzyme sales rose 19.5% annually, aided by continued strong uptake of Dupixent

— Vaccine sales decreased 9.8%, reflecting anticipated weighing of flu vaccine supply towards year-end

— Expects business earnings to grow about 5%, on a constant-currency basis and excluding one-off items, in fiscal 2019

— During the quarter, European Commission approved Dupixent for severe chronic rhinosinusitis

— Achieved positive results from advanced-stage study on Dupixent for severe atopic dermatitis in children

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Most Popular

Does Unity Software (U) stock has more room to run?

Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a

PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant

PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the

Does the virus-driven boom make Electronic Arts (EA) a good investment?

With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top